Normoblastemia in COVID-19 patients is associated with more severe disease and adverse outcome.

ABSTRACT:

Objectives

The clinical, pathological, and laboratory correlates of normoblastemia in COVID-19 patients have not been adequately explored. We sought to assess the frequency of normoblastemia in COVID-19, its association with other markers of disease, as well as other clinical outcomes.

Methods

All COVID-19 patients seen at our institution with at least one automated complete blood count (aCBC) evaluation from March to May 2020 were included in this retrospective cohort analysis. Results of aCBC and tests for markers of the acute phase response performed within 5 days before the first COVID-19 positive test and 14 days after the last positive test were reviewed. We also evaluated histologic features of the reticuloendothelial system of COVID-19 decedents.

Results

Among

SUBMITTER: Ofori K 

PROVIDER: S-EPMC10560885 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature